Background: Pre-eclampsia (PE) is an idiopathic specific syndrome that affects every organ system during pregnancy.It is a leading cause of both fetal and maternal morbidity and mortality worldwide. Setting: Antenatal and Obstetric Department in Azadi Teaching Hospital. Study design: Case-Control study (prospective). Duration: From April - December 2017.
Patients and methods: The study included 90 pregnant women, who were divided into three groups. 30 normotensive women (control), 30 women with mild pre-eclampsia and last 30 were with severe pre-eclampsia.
Results: Plasma level of Copeptin were 6.87 pmol/l in normotensive pregnant group, 51.70 pmol/l in mild pre-eclamptic group and 54.17 pmol/l in severe pre-eclamptic group (p-value<0.05). Copeptin was significantly elevated in pre-eclamptic subjects compared with controls and in severe pre-eclamptic group compared with mild ones. Assessing the diagnostic property of Copeptin for PE, (2) still births were recorded in severe PE, while no still births in mild PE and controls. Copeptin levels in pre-eclamptic patients with adverse neonatal outcomes as low birth weight, admission to NICU were significantly higher than the normotensive group.
Conclusion: This research suggest that increased maternal levels of Copeptin may be involved in the pathogenesis of pre-eclampsia and it may be useful in the assessment of the severity of the disease in the third trimester and this associated with adverse perinatal outcomes